BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies are
looking to take an increasingly hard line when determining whether a new drug provides added value to
patients compared with existing therapies. However, with regards ..."
BMI View: The UK government's implementation of an almost 4% price cut on medicines in 2014, under a
five-year agreement to slow inflation in the GBP11bn (US$15bn) annual National Health Service (NHS)
medicines budget, will work against the country's business environm ..."
BMI View: We continue to believe that increased commercial potential for private insurance companies is
being created through the National Health Service (NHS). Our view is supported by developments such as
the replacement in April 2013 of 152 Primary Care Trusts (PCTs) with 21 ..."
BMI View: We are relatively optimistic about the longer-term performance of the UK's pharmaceutical market, on account of rising demand for services and treatment, stimulated by factors such as an ageing population and increased health awareness. However, over the five years to 2 ..."
Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing ..."